May 1, 2018 / 11:26 AM / 3 months ago

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

May 1 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

* REGENERON PHARMACEUTICALS - EXPRESS SCRIPTS HAS SELECTED PRALUENT AS EXCLUSIVE PCSK9 INHIBITOR THERAPY ON ITS NATIONAL PREFERRED FORMULARY AS OF JULY 1

* REGENERON PHARMACEUTICALS INC - EXPRESS SCRIPTS TO PASS ON SAVINGS TO ELIGIBLE PATIENTS FROM PARTICIPATING COMMERCIAL HEALTH PLANS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below